(Q41157722)

27 September 2017

1 reference

title

Cost-effective treatment of coronary artery disease--the new imperative (English)

1 reference

27 September 2017

Superko HR

1

1 reference

27 September 2017

publication date

1 August 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

19

1 reference

27 September 2017

issue

8

1 reference

27 September 2017

page(s)

650-655

1 reference

Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

Cost and health implications of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

Prognostic significance of progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Cholesterol and cost-effectiveness. Implications for practice, policy, and research

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Drug therapy and the prevention of atherosclerosis in humans.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Low-density lipoprotein density and atherosclerosis. Unraveling the connection

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

The internal mammary artery: the ideal coronary bypass graft?

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190813

7 January 2021

Identifiers

DOI

10.1002/CLC.4960190813

1 reference

27 September 2017

1 reference